28 August 2025 | 2:23AM HKT Giant Biogene Holding (2367.HK) Earnings review: 1H25 sales/NI inline with OP beat on better managed ROI; Guidance unchanged; Buy 2367.HK 12m Price Target: HK$71.00 Price: HK$54.85 Upside: 29.4% | | 12/24 | 12/25E | 12/26E | 12/27E | | --- | --- | --- | --- | --- | | Revenue (Rmb mn) New | 5,538.8 | 6,920.8 | 8,782.7 | 10,406.4 | | Revenue (Rmb mn) Old | 5,538.8 | 6,933.6 | 8,787.7 | 10,360.5 | | EBITDA (Rmb mn) | 2,331.1 | 2,698.1 | 3,331.7 | 3,896.8 | | EPS (Rmb) New | 2.10 | 2 ...

ZEELAND, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the three months ended March 31, 2025. 1st Quarter 2025 Summary Net sales of $576.8 million, a 2% decrease compared to the first quarter of 2024, versus light vehicle production that was down 3% quarter over quarter in the Company's primary market ...